Have these listed companies that have transitioned to "biomanufacturing" started making profits?
6 1,Tianhe BioTwo key signals were released on the investor interaction platform: Phase I of the synthetic biology production base is expected to reach full capacity by 2026, and products such as ergothioneine have already achieved sales in Japan and South Korea.
This global "hidden champion" of antibiotic intermediates is nowFull production + global expansiondriven by a dual-wheel strategy, we are accelerating into the new track of synthetic biology.
[Why the Leader in Antibiotic Intermediates "Crosses Over"?]
Chuanning Biological's traditional label isGlobal leader in antibiotic intermediatesCore products including erythromycin thionocyanate, penicillin intermediates, and cephalosporin intermediates rank among the top globally in production volume. Leveraging Xinjiang Yili's energy and raw material advantages, its production costs are more than 50% lower than those in mainland China.
In early 2026, as India implemented the 6-APA minimum import price, industry quotes gradually adjusted. Product prices bottomed out and began to recover, providing stable cash flow support for the company's transformation.
Core business is the anchor; transformation gives you confidence.
The "Three Major Milestones" of Synthetic Biology
Tianming Bio's transformation isn't just talk—it's real, tangible progress.
The first milestone is achieving production capacity.Phase I of the synthetic biology production base is ramping up as planned. Scaled-up production has been achieved for products including bisabolene, ergothioneine, and 5-hydroxytryptophan. The company has confirmed it will fully implement its full-capacity target through process optimization and capacity ramp-up.
The second milestone is breaking through in international markets.In 2, Chuaning Bio partnered with Japanese distributor Iwase Cosmetics Co., Ltd. Founded in 1931, Iwase Cosmetics is a leading Japanese supplier of personal care ingredients, offering over 4000 cosmetic raw materials annually. Under the agreement, Iwase will serve as Chuaning's exclusive distributor in Japan, representing core products such as bisabolol, squalane, ergothioneine, and inositol. Chuaning's differentiated advantage—"biomanufacturing + green production"—is now entering one of the world's most demanding markets.
The third milestone is forward-looking positioning.Excluding synthetic biology products, the methanol protein project at Chuaning Bio has completed pilot testing and is expected to submit application materials to the Ministry of Agriculture and Rural Affairs in the second half of 2026. Targeting the non-grain protein sector, this project is poised to become the company's next growth engine.
Three steps forward, one foot at a time: Chuaning Biological's transformation path is clear and solid.
[Not Just Chuaning: A Wave of Companies Is Pivoting]
Tianjin Tianning Biotechnology is not an isolated case. Amidst the surge in synthetic biology, a group of A-share listed companies are transitioning from their traditional core businesses into the bio-manufacturing sector, with some already entering the harvest phase.
Cathay Biotech: A Decade of Refining Bio-Based Materials
Cathay Biotech (688065.SH) is the most typical long-termist in the field of biomanufacturing. With over two decades of deep expertise, the company was the first to fully integrateStrain, Fermentation, Purification, Polymerization, Downstream ApplicationsThe only company globally with a full industrial chain, achieving commercial-scale production of all long-chain dicarboxylic acid series and 10,000-ton polymer-grade bio-based pentamethylene diamine.
In 5, the product was successfully integrated into Changan Kaicheng Robovan autonomous delivery vehicles, with a plan to equip 3.5 thousand units within three years, achieving breakthroughs in lightweighting and high strength.
Lude Technology: Brewing Protein Feed from Distillers' Grains
Lude Technology has reached a performance inflection point with its bio-fermented feed production from spent grain. In the first quarter of 2026, revenue reached 1.10 billion yuan, up 74.60% year-over-year; net profit hit 1104 million yuan, surging 780.45% year-over-year.
The company is advancing multiple bases toward full production capacity and has already implemented price increases. Moving forward, it will focus on high-value-added raw materials for synthetic biology.
Lukang Pharmaceutical: Synthetic Biology Product Revenue Surpasses 1.1 Billion Yuan
Lukang Pharmaceutical is gradually transitioning from traditional microbial fermentation to the application of synthetic biotechnology. The company'sWorld's first trans-aconitic acid synthetic biomanufacturing projectBecame operational in 2026 1, achieving mass production at the 100-ton level.
Lukang Pharma continues to build a general biotechnology platform for biosynthesis and accelerates the industrialization of new products.
China Resources Double-Crane: Aiming to Become a Leading Enterprise and Benchmark in Synthetic Biology
China Resources Shuanghe has been developing synthetic biology since 2022. Through technological empowerment, its subsidiary Shenzhou Bio has significantly reduced the cost and substantially increased the production of its core product Coenzyme Q10. The company has clearly positioned synthetic biology as its "second growth curve." All seven technology platforms have been established, with over 20 R&D projects in the pipeline and 6 projects advancing to pilot-scale validation. Currently, all seven technology platforms are fully operational, supporting more than 20 R&D projects, among which 6 have entered the pilot validation phase. Some projects have been selected as flagship products for the first batch of bio-manufacturing initiatives by the Ministry of Industry and Information Technology.
[The Window Is Open: National Strategy and a Trillion-Dollar Market]
Published in 6 1QiushiA magazine published an important article by General Secretary Xi Jinping titled "Forward-Looking Layout and Development of Future Industries," which clearly states: "The Fourth Plenary Session of the 20th CPC Central Committee proposed to promote..."Quantum technology, biological manufacturing, hydrogen and nuclear fusion energy, brain-computer interfaces, embodied intelligence, and sixth-generation mobile communications have emerged as new economic growth drivers."These areas represent the key focus for China's future industrial development during the '15th Five-Year Plan' period. We must concentrate efforts, implement precise policies, and ensure significant progress." The General Secretary emphasized adhering to the principle of "industries pose questions, technology provides answers," while guiding localities to develop according to their specific conditions and preventing blind imitation.This important speech has accelerated the bio-manufacturing industry.
Under the guidance of General Secretary's spirit, national policies are being implemented rapidly. In 5, eight ministries and commissions—including the Ministry of Natural Resources and the National Development and Reform Commission (NDRC)—jointly issued "Guidance on Accelerating High-Quality Development of Marine Drugs and Functional Products." This marks the first top-level policy document at the national level for the marine biomedicine industry, setting a target to exceed 1300 billion yuan in industrial value-added by 2030. At this year's National People's Congress and Chinese People's Political Consultative Conference sessions, NDRC Director Zheng Shanjie explicitly designated bio-manufacturing as one of six key future industries for strategic development.
From an industrial foundation perspective, China's current bio-manufacturing annual output value exceeds 1.1 trillion yuan, with fermentation capacity accounting for over 70% of the global total. The National Development and Reform Commission's Institute of Macroeconomic Research projects that by 2030, a trillion-yuan bio-manufacturing industry cluster with global competitiveness will emerge.In this transformation, biomanufacturing stands at a pivotal moment—transitioning from concept to industry. Companies that first close the loop from lab to production line will undoubtedly seize the high ground in future competition.
2026 Yimao Bio-Pharmaceutical Manufacturing Exhibition
2026 BIO-TECH China 2025 will be held in Shanghai from 8 to 28.At the exhibition, we will invite2000+Attendee,100+Speaker,20+Premium exhibitors, featuring "Exhibitions - Products - Conferences - PartnershipsFour core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."
